LT3754B - Method for preparating of pharmaceutical composition - Google Patents
Method for preparating of pharmaceutical composition Download PDFInfo
- Publication number
- LT3754B LT3754B LTIP1660A LTIP1660A LT3754B LT 3754 B LT3754 B LT 3754B LT IP1660 A LTIP1660 A LT IP1660A LT IP1660 A LTIP1660 A LT IP1660A LT 3754 B LT3754 B LT 3754B
- Authority
- LT
- Lithuania
- Prior art keywords
- tampon
- gel
- weight
- pharmaceutical composition
- mucosa
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims description 40
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 208000019802 Sexually transmitted disease Diseases 0.000 claims abstract description 20
- 210000004877 mucosa Anatomy 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 14
- 230000035515 penetration Effects 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 14
- 230000009471 action Effects 0.000 claims description 13
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 12
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 12
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 12
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 239000002270 dispersing agent Substances 0.000 claims description 11
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 11
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 10
- 229920004918 nonoxynol-9 Polymers 0.000 claims description 9
- 229940087419 nonoxynol-9 Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000000840 anti-viral effect Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 229960001231 choline Drugs 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000000934 spermatocidal agent Substances 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 229960001716 benzalkonium Drugs 0.000 claims 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000006261 foam material Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 16
- 241000894006 Bacteria Species 0.000 abstract description 5
- 238000011200 topical administration Methods 0.000 abstract description 4
- 239000013543 active substance Substances 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000499 gel Substances 0.000 description 52
- 239000002775 capsule Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000001215 vagina Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000004400 mucous membrane Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000005470 impregnation Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000001568 sexual effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000001150 spermicidal effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 229920005830 Polyurethane Foam Polymers 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 241000224527 Trichomonas vaginalis Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000002730 additional effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- -1 siloxanes Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8809418 | 1988-07-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTIP1660A LTIP1660A (en) | 1995-07-25 |
| LT3754B true LT3754B (en) | 1996-03-25 |
Family
ID=9368330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTIP1660A LT3754B (en) | 1988-07-11 | 1993-12-22 | Method for preparating of pharmaceutical composition |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US5439685A (ro) |
| EP (1) | EP0351301B1 (ro) |
| JP (1) | JPH0774164B2 (ro) |
| KR (1) | KR0143231B1 (ro) |
| CN (1) | CN1035038C (ro) |
| AP (1) | AP108A (ro) |
| AR (1) | AR243381A1 (ro) |
| AT (1) | ATE97570T1 (ro) |
| BR (1) | BR8903523A (ro) |
| CA (1) | CA1341304C (ro) |
| CZ (1) | CZ280722B6 (ro) |
| DD (1) | DD283932A5 (ro) |
| DE (1) | DE68910892T2 (ro) |
| DK (1) | DK173527B1 (ro) |
| ES (1) | ES2062065T3 (ro) |
| FI (1) | FI101595B (ro) |
| HK (1) | HK131095A (ro) |
| HU (1) | HU206634B (ro) |
| IE (1) | IE63115B1 (ro) |
| IL (1) | IL90910A (ro) |
| LT (1) | LT3754B (ro) |
| LV (1) | LV10573B (ro) |
| MA (1) | MA22036A1 (ro) |
| MD (1) | MD406C2 (ro) |
| MX (1) | MX170801B (ro) |
| MY (1) | MY106242A (ro) |
| NO (1) | NO178843C (ro) |
| NZ (1) | NZ229891A (ro) |
| OA (1) | OA09123A (ro) |
| PL (1) | PL161848B1 (ro) |
| PT (1) | PT91108B (ro) |
| RU (1) | RU2065742C1 (ro) |
| SK (1) | SK423889A3 (ro) |
| TN (1) | TNSN89074A1 (ro) |
| TR (1) | TR28353A (ro) |
| UA (1) | UA26124A (ro) |
| YU (1) | YU47899B (ro) |
| ZA (1) | ZA895263B (ro) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02258718A (ja) * | 1989-03-31 | 1990-10-19 | Nippon Kayaku Co Ltd | ペースト状基剤及び製剤 |
| US5795870A (en) * | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
| US5693769A (en) * | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
| IT1255450B (it) * | 1992-06-30 | 1995-10-31 | Montefarmaco Spa | Uso di acidi biliari come agenti antivirali |
| WO1995003056A1 (en) * | 1993-07-19 | 1995-02-02 | Tokyo Tanabe Company Limited | Hepatitis c virus proliferation inhibitor |
| DE4341139C1 (de) * | 1993-12-02 | 1995-04-13 | Upmeyer Hans Juergen | Dimeticon zur Behandlung von Aphthen |
| US5667492A (en) * | 1994-10-07 | 1997-09-16 | Columbia Laboratories, Inc. | Use and composition of an anti-sexually transmitted diseases formulation |
| FR2728464B1 (fr) * | 1994-12-22 | 1997-04-30 | Innothera Lab Sa | Forme galenique unitaire, son procede d'obtention et ses utilisations |
| US5700679A (en) * | 1996-06-07 | 1997-12-23 | Novavax, Inc. | Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity |
| AU4214497A (en) * | 1996-09-12 | 1998-04-02 | Simon Everard Barton | Composition comprising an antiviral or antibacterial agent for preventing transmission of diseases |
| US6287286B1 (en) * | 1998-08-25 | 2001-09-11 | Kimberly-Clark Worldwide, Inc. | Absorbent article having a reduced viability of candida albicans |
| US8173709B2 (en) * | 1999-09-22 | 2012-05-08 | Quadex Pharmaceuticals, Llc | Anti-infective methods for treating pathogen-induced disordered tissues |
| US6759434B2 (en) | 1999-09-22 | 2004-07-06 | B. Ron Johnson | Anti-infective compositions, methods and systems for treating disordered tissue |
| US6211243B1 (en) | 1999-09-22 | 2001-04-03 | B. Ron Johnson | Methods for treating cold sores with anti-infective compositions |
| US20050232868A1 (en) * | 1999-10-19 | 2005-10-20 | The Procter & Gamble Company | Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions |
| FR2803208A1 (fr) * | 1999-12-29 | 2001-07-06 | Jean Bastien Pasquini | Tampon periodique antiseptique et son procede de preparation |
| AU2001243431B2 (en) * | 2000-03-07 | 2006-05-25 | Rush University Medical Center | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
| GB2414394B (en) * | 2001-04-11 | 2006-01-11 | Playtex Products Inc | Use of a catamenial tampon which comprises a non-ionic surfactant for the treatment of vaginal malodour |
| GB2415626B (en) * | 2001-04-11 | 2006-03-08 | Playtex Products Inc | Use of a catamenial tampon which comprises a cationic surfactant for the treatment of vaginal malodor |
| US8093446B2 (en) * | 2001-04-11 | 2012-01-10 | Playtex Products, Inc. | Fibrous absorbent articles having malodor counteractant |
| SE0102152L (sv) * | 2001-06-18 | 2002-12-19 | Sca Hygiene Prod Ab | Ny produkt |
| SI1506781T1 (ro) * | 2003-11-03 | 2005-08-31 | Volkmann Peter Hansen | |
| BRPI0615411A2 (pt) * | 2005-08-29 | 2012-12-04 | Sepsicure L L C | uso de um ácido da bìlis ou de um sal de ácido da bìlis e um fosfolipìdeo |
| DE102006020644A1 (de) * | 2006-04-28 | 2007-10-31 | Bayer Innovation Gmbh | Antiseptikahaltige Silikonelastomere |
| US8062631B2 (en) | 2006-09-28 | 2011-11-22 | Clji I.P. Company, Llc | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
| US8409557B2 (en) | 2006-09-28 | 2013-04-02 | Clji Ip Company, Llc | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
| AU2012203566B1 (en) * | 2008-03-27 | 2013-09-12 | Clji I.P. Company, Llc | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
| KR101130754B1 (ko) | 2010-06-25 | 2012-03-28 | 제일약품주식회사 | 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물 |
| BR112013011744B1 (pt) * | 2010-11-12 | 2021-04-27 | The University Of Utah Research Foundation | Dispositivo intravaginal para distribuição controlada de lubrificantes |
| CN103619341A (zh) | 2011-04-19 | 2014-03-05 | Arms制药有限公司 | 抑制有害微生物的方法及其阻隔形成组合物 |
| US10426761B2 (en) | 2011-04-19 | 2019-10-01 | Arms Pharmaceutical, Llc | Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof |
| CA2781379C (en) | 2012-03-26 | 2013-09-03 | Clji Ip Company, Llc | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
| US9125911B2 (en) | 2013-03-14 | 2015-09-08 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered tissues |
| US9549930B2 (en) | 2013-03-14 | 2017-01-24 | Quadex Pharmaceuticals, Llc | Combined systemic and topical treatment of disordered and/or prodromal stage tissue |
| US9463180B2 (en) | 2013-03-14 | 2016-10-11 | Quadex Pharmaceuticals, Llc | Treatment of molluscum contagiosum |
| DE102020131233A1 (de) * | 2020-11-25 | 2022-05-25 | Netzsch Trockenmahltechnik Gmbh | Verfahren zur herstellung eines homogenisierten gemischs aus kohlenstoff, schwefel und ptfe |
| KR102399883B1 (ko) * | 2021-02-09 | 2022-05-20 | 재단법인대구경북과학기술원 | 압출용 복합고분자 펠릿 및 이의 제조방법 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0113998A2 (en) | 1982-12-22 | 1984-07-25 | Herpes Pharmaceutical, Inc. | Composition and treatment for herpes simplex viral infections |
| EP0285285A2 (en) | 1987-03-17 | 1988-10-05 | Public Health Laboratory Service Board | Method and composition for the treatment and prevention of viral infections |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1161484A (en) * | 1965-08-20 | 1969-08-13 | Mediline Ag | Toilet Preparation |
| SE353658B (ro) * | 1967-06-13 | 1973-02-12 | Dow Corning | |
| US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US3770648A (en) * | 1971-07-12 | 1973-11-06 | Bristol Myers Co | Anhydrous aerosol foam |
| BE791632A (fr) * | 1971-11-20 | 1973-05-21 | Schering Ag | Supports a base de caoutchouc siliconique pour agents medicamenteux |
| US4393871A (en) * | 1977-06-27 | 1983-07-19 | Vli Corporation | Vaginal device |
| US4228797A (en) * | 1978-09-25 | 1980-10-21 | Dickey Richard P | Intravaginal contraception method |
| ZA827582B (en) * | 1981-11-06 | 1983-08-31 | Ansell Inc | Spermicidal condom |
| EP0081370A1 (en) * | 1981-12-07 | 1983-06-15 | Syntex (U.S.A.) Inc. | Disposable intravaginal contraceptive devices releasing 1-substituted imidazoles |
| DE3204124A1 (de) * | 1982-02-06 | 1983-08-18 | Bayer Ag, 5090 Leverkusen | Antimykotische tampons mit hoher wirkstoff-freisetzung |
| DE3346641A1 (de) * | 1983-12-23 | 1985-07-04 | Dynamit Nobel Ag, 5210 Troisdorf | Silanmodifizierte estergemische |
| GB8402748D0 (en) * | 1984-02-02 | 1984-03-07 | Dunlop Ltd | Intravaginal device |
| NL8600929A (nl) * | 1986-04-11 | 1987-11-02 | Fundatech Sa | Werkwijze voor het vervaardigen van een gemedicateerd wegwerp-pessarium en gemedicateerd wegwerp-pessarium. |
| IT1213323B (it) * | 1986-08-07 | 1989-12-20 | Crinos Industria Farmaco | Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida |
| US4952411A (en) * | 1987-02-25 | 1990-08-28 | Trustees Of Columbia University In The City Of New York | Method of inhibiting the transmission of AIDS virus |
| FR2614525B1 (fr) * | 1987-04-29 | 1995-11-10 | Jacques Augros | Tampon en eponge elastique, notamment tampon vaginal |
| US4922928A (en) * | 1988-08-17 | 1990-05-08 | Michael Burnhill | Vaginal device |
-
1989
- 1989-07-07 NO NO892826A patent/NO178843C/no unknown
- 1989-07-10 MA MA21844A patent/MA22036A1/fr unknown
- 1989-07-10 UA UA4614544A patent/UA26124A/uk unknown
- 1989-07-10 RU SU4614544/14A patent/RU2065742C1/ru not_active IP Right Cessation
- 1989-07-10 IE IE221889A patent/IE63115B1/en not_active IP Right Cessation
- 1989-07-10 AT AT89401979T patent/ATE97570T1/de not_active IP Right Cessation
- 1989-07-10 FI FI893340A patent/FI101595B/fi not_active IP Right Cessation
- 1989-07-10 DE DE89401979T patent/DE68910892T2/de not_active Expired - Fee Related
- 1989-07-10 TN TNTNSN89074A patent/TNSN89074A1/fr unknown
- 1989-07-10 CA CA000605271A patent/CA1341304C/fr not_active Expired - Fee Related
- 1989-07-10 HU HU893459A patent/HU206634B/hu not_active IP Right Cessation
- 1989-07-10 MX MX016734A patent/MX170801B/es unknown
- 1989-07-10 DK DK198903402A patent/DK173527B1/da not_active IP Right Cessation
- 1989-07-10 MY MYPI89000940A patent/MY106242A/en unknown
- 1989-07-10 PT PT91108A patent/PT91108B/pt not_active IP Right Cessation
- 1989-07-10 EP EP89401979A patent/EP0351301B1/fr not_active Expired - Lifetime
- 1989-07-10 AR AR89314348A patent/AR243381A1/es active
- 1989-07-10 IL IL9091089A patent/IL90910A/en not_active IP Right Cessation
- 1989-07-10 ES ES89401979T patent/ES2062065T3/es not_active Expired - Lifetime
- 1989-07-10 YU YU135789A patent/YU47899B/sh unknown
- 1989-07-11 NZ NZ229891A patent/NZ229891A/xx unknown
- 1989-07-11 ZA ZA895263A patent/ZA895263B/xx unknown
- 1989-07-11 KR KR1019890009850A patent/KR0143231B1/ko not_active Expired - Lifetime
- 1989-07-11 CN CN89104829A patent/CN1035038C/zh not_active Expired - Lifetime
- 1989-07-11 CZ CS894238A patent/CZ280722B6/cs not_active IP Right Cessation
- 1989-07-11 AP APAP/P/1989/000133A patent/AP108A/en active
- 1989-07-11 DD DD89330678A patent/DD283932A5/de not_active IP Right Cessation
- 1989-07-11 TR TR00603/89A patent/TR28353A/xx unknown
- 1989-07-11 PL PL89280531A patent/PL161848B1/pl unknown
- 1989-07-11 JP JP1177278A patent/JPH0774164B2/ja not_active Expired - Fee Related
- 1989-07-11 BR BR898903523A patent/BR8903523A/pt not_active IP Right Cessation
- 1989-07-11 OA OA59610A patent/OA09123A/xx unknown
- 1989-07-11 SK SK4238-89A patent/SK423889A3/sk unknown
-
1992
- 1992-12-22 US US07/995,522 patent/US5439685A/en not_active Expired - Lifetime
-
1993
- 1993-02-25 LV LVP-93-140A patent/LV10573B/en unknown
- 1993-12-22 LT LTIP1660A patent/LT3754B/lt not_active IP Right Cessation
-
1994
- 1994-12-30 MD MD95-0089A patent/MD406C2/ro unknown
-
1995
- 1995-08-17 HK HK131095A patent/HK131095A/xx not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0113998A2 (en) | 1982-12-22 | 1984-07-25 | Herpes Pharmaceutical, Inc. | Composition and treatment for herpes simplex viral infections |
| EP0285285A2 (en) | 1987-03-17 | 1988-10-05 | Public Health Laboratory Service Board | Method and composition for the treatment and prevention of viral infections |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3754B (en) | Method for preparating of pharmaceutical composition | |
| US6328991B1 (en) | Composition and method for prevention of sexually transmitted diseases, including aids | |
| US5527534A (en) | Vaginal sponge delivery system | |
| Amaral et al. | Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel | |
| WO1994008536A9 (en) | Vaginal sponge delivery system | |
| EP0727988B1 (en) | Aids prophylactic lubricating composition and devices for its use | |
| KR20120099473A (ko) | Ｈｉｖ 감염 예방을 위한 히드록시타이로졸 및 유도체의 국소적 사용 | |
| Omar et al. | The future of microbicides | |
| Creatsas et al. | Safety and tolerability of the new contraceptive sponge Protectaid® | |
| HRP921074A2 (en) | A process for the production of a preparation for preventing sexual deseases from spreading | |
| Oshio et al. | Spermicidal activity of menfegol‐coated condom: Spermicide Aktivität eines Menfegol‐beschichteten Kondoms | |
| Venere | On research: new contraceptive gel prevents pregnancy and STDs | |
| Forrester et al. | Treatment of trichuris infection with albendazole | |
| Lumbar | 40 JOULY 6, 1963 ANY QUESTIONS? BRITISH MEDICAL JOURNAL | |
| Ring | APTI ijper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20031222 |